Fresenius Medical Care (NYSE:FMS) reported fourth-quarter financial results that exceeded Wall Street expectations, signaling a robust conclusion to its fiscal 2025.
The dialysis services giant posted a net income of $380.7 million for the quarter.
On a per-share basis, the company earned 66 cents.
When adjusted for non-recurring costs—including restructuring charges and one-time items—earnings reached 83 cents per share.
This comfortably cleared the 67-cent consensus estimate from analysts surveyed by Zacks Investment Research.
Revenue for the three-month period reached $5.9 billion, driven by stable demand for its specialized kidney care services and a continued focus on operational efficiency within its clinic network.
For the full year 2025, the Bad Homburg-based company reported a total profit of $1.11 billion, or $1.90 per share.
Total annual revenue stood at $22.2 billion.
The results reflect a year of transition for the company as it navigates a simplified operating model and a leaner corporate structure.
Following the deconsolidation of its dialysis subsidiary from the parent Fresenius SE, Fresenius Medical Care has prioritized margin improvement over aggressive footprint expansion.